{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:24Z","timestamp":1786121184112,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate stage-dependent performance of same-session [18F]FDG PET\/contrast-enhanced CT (PET\/ceCT) for initial breast cancer staging and PET\/ceCT-detected relapse patterns during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-centre study included a primary staging cohort with one index PET\/ceCT per patient and a longitudinal cohort of follow-up\/restaging examinations. PET\/ceCT-derived endpoints were assessed against clinically adjudicated reference standards established through multidisciplinary team review, pathology when available and follow-up imaging. SUVmax and ceCT lesion diameter were analysed as exploratory biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The staging cohort included 116 patients. Baseline stage was evaluable in 106 patients: 65 had cN-positive disease, 9 had cT3-4 cN0 disease and 32 had cT1-2 cN0 disease. Overall nodal staging performance showed sensitivity 64.8%, specificity 88.9%, PPV 92.0%, NPV 56.1% and accuracy 72.9%. In cT3-4 and\/or cN-positive disease, PET-positive nodal findings had a PPV of 100%. Baseline M-stage assessment was limited by the low number of clinically confirmed M1 cases. SUVmax correlated with Ki-67 (rho\u2009=\u20090.322,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003, q\u2009=\u20090.022). The longitudinal cohort included 176 patients and 429 examinations. In 311 adjudicated examinations, restaging performance for disease progression showed sensitivity 100%, specificity 93.5%, PPV 97.3%, NPV 100% and accuracy 98.1%. First confirmed relapse was multiorgan\/multisystem in 48\/82 patients and visceral-only in 15\/82; visceral conversion occurred in 5\/16 patients with initial bone-only or nodal\/locoregional relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Same-session [18F]FDG PET\/ceCT showed greatest baseline utility in higher-risk breast cancer and was useful for longitudinal characterization of relapse phenotype and metastatic evolution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08077-w","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:34:26Z","timestamp":1786073666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage-dependent performance and molecular subtype-specific relapse patterns on same-session [18F]FDG PET\/contrast-enhanced CT in breast cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-8858","authenticated-orcid":false,"given":"Agostino","family":"Chiaravalloti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyqyri","family":"Samarxhiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Portarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Flaminio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"D\u2019Ascenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"8077_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andre F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382.","journal-title":"Ann Oncol"},{"key":"8077_CR2","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA. Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8077_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","volume":"46","author":"S Han","year":"2021","unstructured":"Han S, Choi JY. Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer: a systematic review and meta-analysis. Clin Nucl Med. 2021;46:271\u201382.","journal-title":"Clin Nucl Med"},{"key":"8077_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-020-05929-3","volume":"185","author":"M Vogsen","year":"2021","unstructured":"Vogsen M, Jensen JD, Christensen IY, Gerke O, Jylling AMB, Larsen LB, et al. FDG-PET\/CT in high-risk primary breast cancer: a prospective study of stage migration and clinical impact. Breast Cancer Res Treat. 2021;185:145\u201353.","journal-title":"Breast Cancer Res Treat"},{"key":"8077_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s13193-021-01299-4","volume":"12","author":"S Bhoriwal","year":"2021","unstructured":"Bhoriwal S, Deo SVS, Kumar R, Thulkar S, Gogia A, Sharma DN, et al. A prospective study comparing the role of 18 FDG PET-CT with contrast-enhanced computed tomography and Tc99m bone scan for staging locally advanced breast cancer. Indian J Surg Oncol. 2021;12:266\u201371.","journal-title":"Indian J Surg Oncol"},{"key":"8077_CR6","doi-asserted-by":"publisher","first-page":"101567","DOI":"10.1016\/j.suronc.2021.101567","volume":"38","author":"T Davidson","year":"2021","unstructured":"Davidson T, Shehade N, Nissan E, Sklair-Levy M, Ben-Haim S, Barshack I, et al. PET\/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases. Surg Oncol. 2021;38:101567.","journal-title":"Surg Oncol"},{"key":"8077_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13550-023-00953-y","volume":"13","author":"CM de Mooij","year":"2023","unstructured":"de Mooij CM, Ploumen RAW, Nelemans PJ, Mottaghy FM, Smidt ML, van Nijnatten TJA. The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. EJNMMI Res. 2023;13:5.","journal-title":"EJNMMI Res"},{"key":"8077_CR8","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1007\/s00259-023-06394-y","volume":"50","author":"RD Seban","year":"2023","unstructured":"Seban RD, Arnaud E, Loirat D, Cabel L, Cottu P, Djerroudi L, et al. [18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab. Eur J Nucl Med Mol Imaging. 2023;50:4024\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8077_CR9","doi-asserted-by":"publisher","first-page":"e1646","DOI":"10.1093\/oncolo\/oyae185","volume":"29","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li Y, Chen B, Zhang Y, Xing W, Guo B, et al. 18F-FDG PET\/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis. Oncologist. 2024;29:e1646\u201355.","journal-title":"Oncologist"},{"key":"8077_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1053\/j.semnuclmed.2022.03.004","volume":"52","author":"MG Hildebrandt","year":"2022","unstructured":"Hildebrandt MG, Naghavi-Behzad M, Vogsen M. A role of FDG-PET\/CT for response evaluation in metastatic breast cancer? Semin Nucl Med. 2022;52:520\u201330.","journal-title":"Semin Nucl Med"},{"key":"8077_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2967\/jnumed.121.263358","volume":"64","author":"M Vogsen","year":"2023","unstructured":"Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, et al. Response monitoring in metastatic breast cancer: a prospective study comparing 18F-FDG PET\/CT with conventional CT. J Nucl Med. 2023;64:355\u201361.","journal-title":"J Nucl Med"},{"key":"8077_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-026-01022-7","author":"A Chiaravalloti","year":"2026","unstructured":"Chiaravalloti A, Vanni G, Verdesca L, Di Biagio D, Tavolozza M, Buonomo OC, Schillaci O. Site-specific patterns of distant relapse on [18F]FDG PET\/contrast-enhanced CT according to molecular subtype in breast cancer: a retrospective cohort study. Nucl Med Mol Imaging. 2026. https:\/\/doi.org\/10.1007\/s13139-026-01022-7.","journal-title":"Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"8077_CR13","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2967\/jnumed.115.157859","volume":"57","author":"D Groheux","year":"2016","unstructured":"Groheux D, Cochet A, Humbert O, Alberini JL, Hindi\u00e9 E, Mankoff D. 18F-FDG PET\/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):S17\u201326.","journal-title":"J Nucl Med"},{"key":"8077_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00249","author":"IS Dayes","year":"2023","unstructured":"Dayes IS, Metser U, Hodgson N, Parpia S, Eisen AF, George R, et al. Impact of 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.23.00249.","journal-title":"J Clin Oncol"},{"key":"8077_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00259-016-3402-9","volume":"43","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, et al. 18F-FDG-PET\/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016;43:1937\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8077_CR16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s00259-017-3709-1","volume":"44","author":"GA Ulaner","year":"2017","unstructured":"Ulaner GA, Castillo R, Wills J, G\u00f6nen M, Goldman DA. 18F-FDG-PET\/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1420\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8077_CR17","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","volume":"44","author":"CC Riedl","year":"2017","unstructured":"Riedl CC, Pinker K, Ulaner GA, Ong L, Baltzer P, Jochelson MS, et al. Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1428\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8077_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/diagnostics9030106","volume":"9","author":"F Helland","year":"2019","unstructured":"Helland F, Henriksen MH, Gerke O, Vogsen M, H\u00f8ilund-Carlsen PF, Hildebrandt MG. FDG-PET\/CT versus contrast-enhanced CT for response evaluation in metastatic breast cancer: a systematic review. Diagnostics (Basel). 2019;9:106.","journal-title":"Diagnostics (Basel)"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08077-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08077-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08077-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:34:27Z","timestamp":1786073667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08077-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":18,"alternative-id":["8077"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08077-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the local Ethics Committee.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective design of the study and the use of anonymized clinical and imaging data, the requirement for written informed consent was waived by the local Ethics Committee.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}